The invention WO2008095357 provides the use of a recombinant genetic vector comprising at least one copy of an expressed gene encoding StatδA, and comprising at least one copy of a Statδ inhibitor, for the development of a drug for the treatment of SMA or other SMN deficiency in humans. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.